Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced its decision not to continue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic antibody that targets CD70.
The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia (AML). Final results from Janssen's clinical studies of cusatuzumab will be presented in the future.
Janssen will work with argenx to transition the cusatuzumab program back to argenx. Patients currently enrolled in ongoing cusatuzumab clinical trials will continue to be supported through treatment and follow-up.
Janssen entered into the worldwide collaboration and license agreement with argenx in December 2018 to develop and commercialize cusatuzumab in AML and potential additional indications.
